share_log

StockNews.com Downgrades Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold

StockNews.com Downgrades Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold

StockNews.com 将皮耶里斯制药（纳斯达克股票代码：PIRS）的评级下调至
Defense World ·  2023/01/21 15:31

Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday.

皮尔斯制药（纳斯达克股票代码：PIRS — 获取评级） 在周四向客户和投资者发布的研究报告中，StockNews.com的股票分析师将评级从 “买入” 下调至 “持有”。

Pieris Pharmaceuticals Stock Performance

皮尔斯制药股票表现

Shares of NASDAQ PIRS opened at $1.40 on Thursday. The company has a 50-day moving average of $1.07 and a 200 day moving average of $1.30. Pieris Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $3.75. The stock has a market cap of $104.17 million, a PE ratio of -2.98 and a beta of 0.95.

纳斯达克PIRS的股票周四开盘价为1.40美元。该公司的50天移动平均线为1.07美元，200天移动平均线为1.30美元。Pieris Pharmicals创下12个月低点0.85美元，12个月高点为3.75美元。该股的市值为1.0417亿美元，市盈率为-2.98，beta值为0.95。

Get
获取
Pieris Pharmaceuticals
皮耶斯制药
alerts:
警报：

Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Pieris Pharmaceuticals had a negative return on equity of 75.31% and a negative net margin of 121.78%. The firm had revenue of $5.37 million during the quarter, compared to analysts' expectations of $4.51 million. On average, sell-side analysts forecast that Pieris Pharmaceuticals will post -0.63 EPS for the current fiscal year.

Pieris Pharmicals（纳斯达克股票代码：PIRS — Get Rating）最后一次公布季度财报是在11月2日星期三。这家生物技术公司公布了本季度每股收益（0.13美元），比市场普遍预期的0.16美元（0.16美元）高出0.03美元。皮尔斯制药的股本回报率为负75.31％，负净利润率为121.78％。该公司在本季度的收入为537万美元，而分析师的预期为451万美元。平均而言，卖方分析师预测，Pieris Pharmicals将在本财年公布每股收益为-0.63。

Institutional Investors Weigh In On Pieris Pharmaceuticals

机构投资者对皮尔斯制药的看法

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cutter & CO Brokerage Inc. grew its stake in shares of Pieris Pharmaceuticals by 1.5% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 412,229 shares of the biotechnology company's stock valued at $771,000 after buying an additional 6,000 shares during the period. Rafferty Asset Management LLC increased its stake in Pieris Pharmaceuticals by 32.3% during the second quarter. Rafferty Asset Management LLC now owns 29,622 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 7,240 shares during the last quarter. Hsbc Holdings PLC increased its stake in Pieris Pharmaceuticals by 55.6% during the first quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 7,343 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Pieris Pharmaceuticals in the first quarter valued at $32,000. Finally, Blair William & Co. IL lifted its stake in shares of Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company's stock valued at $390,000 after purchasing an additional 10,760 shares during the last quarter. 47.31% of the stock is currently owned by institutional investors and hedge funds.
几家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Cutter & CO Brokerage Inc.在第二季度将其在Pieris Pharmicals的股份增加了1.5％。Cutter & CO Brokerage Inc.在此期间又购买了6,000股股票后，现在拥有这家生物技术公司的412,229股股票，价值77.1万美元。拉弗蒂资产管理有限责任公司在第二季度将其在皮尔斯制药的股份增加了32.3％。Rafferty Asset Management LLC在上个季度又收购了7,240股股票后，现在拥有这家生物技术公司的29,622股股票，价值55,000美元。汇丰控股集团在第一季度将其在皮尔斯制药的股份增加了55.6％。汇丰控股有限公司在上个季度又收购了7,343股股票后，现在拥有这家生物技术公司的20,556股股票，价值63,000美元。Oppenheimer & Co.Inc. 在第一季度收购了Pieris Pharmicals的新股份，价值32,000美元。最后，布莱尔·威廉公司伊利诺伊州在第一季度将其在Pieris Pharmicals的股份提高了9.1％。布莱尔·威廉姆斯公司伊利诺伊州在上个季度又购买了10,760股股票后，现在拥有这家生物技术公司的128,745股股票，价值39万美元。该股票的47.31％目前由机构投资者和对冲基金持有。

Pieris Pharmaceuticals Company Profile

皮尔斯制药公司简介

(Get Rating)

（获取评分）

Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Pieris Pharmicals, Inc是一家处于临床阶段的生物技术公司，从事抗卡林类药物的发现和开发。其产品线包括免疫肿瘤学、呼吸系统和贫血以及其他疾病领域。该公司由克劳斯·沙尔珀和阿恩·斯凯拉于2001年创立，总部位于马萨诸塞州波士顿。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Pieris Pharmaceuticals (PIRS)
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth
  • 免费获取 StockNews.com 关于皮尔斯制药（PIRS）的研究报告的副本
  • MarketBeat Week 回顾 — 1/16 — 1/20
  • Old Dominion 是否表明卡车运输正在刹车？
  • 诺德斯特龙将对降价的恐惧带入零售业
  • 埃克森美孚股票：距离买入点仅几步之遥
  • 高股息收益的必和必拓认为中国将推动 “23” 的增长

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收《皮尔斯制药日报》的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Pieris Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发